Whanin to sign exclusive distribution agreement for Nalmefene in Korea.

Whanin made an exclusive distribution agreement with Biotti Terapis, a biotech company in Finland, on Oct. 26 for the marketing of Nalmefene hydrochloride, an oral anti-alcoholic drug, solely in Korea.

Nalmefene is currently available with an injectable drug in the United States for the treatment of narcotic intoxication, which now has been developed as an oral drug after completing a clinic...